Diffuse alveolar hemorrhage as an early complication of alemtuzumab treatment: A case report of a multiple sclerosis patient and an overview of 14 cases
| Autor: | D. Zemel, Beatrijs H.A. Wokke, B.R.H. Drop, J.W.K. de Beukelaar, S. Dik, B.W. van Oosten, P.E. Westerweel, C.O. Martins Jarnalo |
|---|---|
| Přispěvatelé: | Neurology, Amsterdam Neuroscience - Neuroinfection & -inflammation |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Pediatrics
medicine.medical_specialty business.industry Multiple sclerosis Diffuse alveolar hemorrhage General Medicine Review procedure medicine.disease Early complication 03 medical and health sciences 0302 clinical medicine Neurology Relapsing remitting medicine Alemtuzumab 030212 general & internal medicine Neurology (clinical) Adverse effect business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Multiple Sclerosis and Related Disorders, 47:102614. Elsevier Inc. Multiple Sclerosis and Related Disorders, 47:102614. Elsevier Drop, B R H, Zemel, D, Wokke, B H A, van Oosten, B W, Dik, S, Martins Jarnalo, C O, Westerweel, P E & de Beukelaar, J W K 2021, ' Diffuse alveolar hemorrhage as an early complication of alemtuzumab treatment: A case report of a multiple sclerosis patient and an overview of 14 cases ', Multiple Sclerosis and Related Disorders, vol. 47, 102614 . https://doi.org/10.1016/j.msard.2020.102614 |
| ISSN: | 2211-0348 |
| DOI: | 10.1016/j.msard.2020.102614 |
| Popis: | Alemtuzumab is effective in relapsing remitting multiple sclerosis (RRMS). Serious adverse events have led to a renewed safety reassessment by the European Medicines Agency (EMA), leading to an approval under strict conditions. We report a RRMS patient experiencing diffuse alveolar hemorrhage (DAH) on day 4 of her first alemtuzumab cycle. In addition, we present an overview of the cases of alemtuzumab-induced DAH that were included in EMA's review procedure, additional well documented cases reported to the EMA and those cases reported in the literature. Combining these cases revealed striking similarities. Importantly, DAH was an early complication. All RRMS patients with known outcome showed complete recovery. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect